[
  {
    "slug": "17a-methyl-1-testosterone",
    "title": "17a-Methyl-1-testosterone",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "17a-Methyl-1-testosterone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "17a-Methyl-1-testosterone appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for 17a-Methyl-1-testosterone; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is 17a-Methyl-1-testosterone appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "17a-Methyl-1-testosterone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=17a-Methyl-1-testosterone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "17a-Methyl-1-testosterone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=17a-Methyl-1-testosterone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "17a-Methyl-1-testosterone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "5-amino-1mq",
    "title": "5-amino-1mq",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "5-amino-1mq guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "5-amino-1mq appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for 5-amino-1mq; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is 5-amino-1mq appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "5-amino-1mq: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=5-amino-1mq",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "5-amino-1mq: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=5-amino-1mq",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "5-amino-1mq: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ace-031",
    "title": "ACE-031",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "ACE-031 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ACE-031 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for ACE-031; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is ACE-031 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ACE-031: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ACE-031",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ACE-031: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ACE-031",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ACE-031: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "adamax",
    "title": "Adamax",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Adamax guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Adamax appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Adamax; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Adamax appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Adamax: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Adamax",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Adamax: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Adamax",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Adamax: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "adipotide",
    "title": "Adipotide",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Adipotide guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Adipotide appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Adipotide; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Adipotide appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Adipotide: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Adipotide",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Adipotide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Adipotide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Adipotide: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ahk-cu",
    "title": "AHK-CU",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "AHK-CU guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "AHK-CU appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for AHK-CU; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is AHK-CU appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "AHK-CU: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=AHK-CU",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "AHK-CU: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=AHK-CU",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "AHK-CU: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "aicar",
    "title": "Aicar",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Aicar guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Aicar appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Aicar; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Aicar appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Aicar: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Aicar",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Aicar: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Aicar",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Aicar: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "alprostadil",
    "title": "Alprostadil",
    "aliases": [],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Alprostadil guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Alprostadil appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Alprostadil; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Alprostadil appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Alprostadil: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Alprostadil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Alprostadil: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Alprostadil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Alprostadil: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "anadrol",
    "title": "ANADROL",
    "aliases": [
      "ANADROL(Oxymetholone)"
    ],
    "category": "Oral Compound",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "ANADROL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ANADROL appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for ANADROL; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Compounded or supportive products can vary by concentration and handling requirements.",
      "Verify sterile technique, storage conditions, and route-specific safety.",
      "Escalate persistent intolerance, reactions, or contamination concerns promptly."
    ],
    "providerQuestions": [
      "Is ANADROL appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ANADROL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ANADROL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ANADROL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ANADROL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ANADROL: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=ANADROL",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "anavar",
    "title": "ANAVAR",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "ANAVAR guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ANAVAR appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for ANAVAR; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is ANAVAR appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ANAVAR: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ANAVAR",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ANAVAR: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ANAVAR",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ANAVAR: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "andarine-s4",
    "title": "Andarine S4",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Andarine S4 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Andarine S4 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Andarine S4; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Andarine S4 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Andarine S4: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Andarine%20S4",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Andarine S4: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Andarine%20S4",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Andarine S4: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "androxal-enclomiphene",
    "title": "Androxal(Enclomiphene)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Androxal(Enclomiphene) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Androxal(Enclomiphene) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Androxal(Enclomiphene); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Androxal(Enclomiphene) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Androxal(Enclomiphene): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Androxal",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Androxal(Enclomiphene): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Androxal",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Androxal(Enclomiphene): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "aod-9604",
    "title": "AOD-9604",
    "aliases": [
      "HGH Fragment",
      "AOD9604"
    ],
    "category": "Fat Loss Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "AOD-9604 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. AOD-9604 is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Clinical and clinic protocols commonly report 250-1000 mcg once daily, usually in morning or fasted windows. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for AOD-9604 in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "AOD-9604: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=AOD-9604",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "AOD-9604: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=AOD-9604",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "AOD-9604: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=AOD-9604",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "AOD-9604: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "ara-290",
    "title": "ARA-290",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "ARA-290 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ARA-290 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for ARA-290; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is ARA-290 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ARA-290: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ARA-290",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ARA-290: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ARA-290",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ARA-290: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "arimidex",
    "title": "ARIMIDEX",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "ARIMIDEX guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "ARIMIDEX appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for ARIMIDEX; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is ARIMIDEX appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "ARIMIDEX: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=ARIMIDEX",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "ARIMIDEX: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=ARIMIDEX",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "ARIMIDEX: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "aromasin-exemestane",
    "title": "Aromasin(Exemestane)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Aromasin(Exemestane) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Aromasin(Exemestane) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Aromasin(Exemestane); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Aromasin(Exemestane) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Aromasin(Exemestane): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Aromasin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Aromasin(Exemestane): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Aromasin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Aromasin(Exemestane): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "b12",
    "title": "Vitamin B12",
    "aliases": [
      "Cyanocobalamin",
      "Methylcobalamin",
      "B12"
    ],
    "category": "Vitamin",
    "status": "nutrient",
    "statusLabel": "Nutrient Support",
    "metaDescription": "Vitamin B12 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Vitamin B12 is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Common injectable protocols use 1000-5000 mcg weekly, with frequency individualized to lab status and symptoms. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Administration consistency and lab follow-up dates.",
      "Energy, neurologic, or musculoskeletal symptom trends over weeks.",
      "Route tolerance and adherence barriers."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Vitamin B12 in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Vitamin B12: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Vitamin%20B12&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Vitamin B12: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vitamin%20B12",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Vitamin B12: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Vitamin%20B12",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Vitamin B12: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Vitamin%20B12+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "bac-water",
    "title": "BAC Water",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "BAC Water guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BAC Water appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for BAC Water; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Compounded or supportive products can vary by concentration and handling requirements.",
      "Verify sterile technique, storage conditions, and route-specific safety.",
      "Escalate persistent intolerance, reactions, or contamination concerns promptly."
    ],
    "providerQuestions": [
      "Is BAC Water appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BAC Water: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BAC%20Water",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BAC Water: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BAC%20Water",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BAC Water: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=BAC%20Water",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "bam15",
    "title": "BAM15",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BAM15 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BAM15 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for BAM15; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BAM15 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BAM15: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BAM15",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BAM15: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BAM15",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BAM15: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "bc-boldenone-cyp",
    "title": "BC(Boldenone Cyp)",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BC(Boldenone Cyp) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BC(Boldenone Cyp) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for BC(Boldenone Cyp); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BC(Boldenone Cyp) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BC(Boldenone Cyp): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BC",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BC(Boldenone Cyp): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BC",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BC(Boldenone Cyp): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "beinaglutide",
    "title": "Beinaglutide",
    "aliases": [
      "Benaglutide",
      "Beisu"
    ],
    "category": "GLP-1",
    "status": "regional-approval",
    "statusLabel": "Regional Approval",
    "metaDescription": "Beinaglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Beinaglutide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Published regimens often use 0.1-0.2 mg daily subcutaneous dosing, adjusted to tolerability. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Weekly adherence with exact injection-day drift tracking.",
      "Nausea, reflux, bowel-pattern, and meal-size tolerance logs.",
      "Weight trend slope and appetite-return timing across weekly curve."
    ],
    "safetyFlags": [
      "Regulatory approval may be regional, not universal; confirm local legal/clinical context.",
      "Quality and labeling standards can differ across jurisdictions.",
      "Escalate adverse effects and confirm dose rationale with local licensed clinicians."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Beinaglutide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Beinaglutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Beinaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Beinaglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Beinaglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Beinaglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Beinaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Beinaglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Beinaglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "boron",
    "title": "Boron",
    "aliases": [
      "B"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Boron guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Boron guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize boron dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Boron in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Boron: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Boron-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Boron: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Boron",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Boron: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Boron+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "botulinum-toxin",
    "title": "Botulinum toxin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Botulinum toxin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Botulinum toxin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Botulinum toxin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Botulinum toxin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Botulinum toxin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Botulinum%20toxin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Botulinum toxin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Botulinum%20toxin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Botulinum toxin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "bpc-157",
    "title": "BPC-157",
    "aliases": [
      "Body Protection Compound 157"
    ],
    "category": "Healing Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC-157 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. BPC-157 is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Clinic and research-use protocols commonly report 250-1000 mcg daily in divided or once-daily dosing. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for BPC-157 in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC-157: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=BPC-157",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC-157: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=BPC-157",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC-157: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC-157",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "BPC-157: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "bpc-500mcg-plus-tb500-500mcg-blend",
    "title": "BPC 500mcg+TB500 500mcg Blend",
    "aliases": [],
    "category": "Compound Blend",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC 500mcg+TB500 500mcg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BPC 500mcg+TB500 500mcg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for BPC 500mcg+TB500 500mcg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BPC 500mcg+TB500 500mcg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC 500mcg+TB500 500mcg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC%20500mcg%2BTB500%20500mcg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC 500mcg+TB500 500mcg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC%20500mcg%2BTB500%20500mcg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC 500mcg+TB500 500mcg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "bpc157-10mg-plus-tb500-10mg-blend",
    "title": "BPC157 10mg+TB500 10mg Blend",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC157 10mg+TB500 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BPC157 10mg+TB500 10mg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for BPC157 10mg+TB500 10mg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BPC157 10mg+TB500 10mg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC157 10mg+TB500 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC157%2010mg%2BTB500%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC157 10mg+TB500 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC157%2010mg%2BTB500%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC157 10mg+TB500 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "bpc157-5mg-plus-tb500-5mg-blend",
    "title": "BPC157 5mg+TB500 5mg Blend",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BPC157 5mg+TB500 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BPC157 5mg+TB500 5mg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for BPC157 5mg+TB500 5mg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BPC157 5mg+TB500 5mg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BPC157 5mg+TB500 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BPC157%205mg%2BTB500%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BPC157 5mg+TB500 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BPC157%205mg%2BTB500%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BPC157 5mg+TB500 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "bu-equipoise",
    "title": "BU(EQUIPOISE)",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "BU(EQUIPOISE) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "BU(EQUIPOISE) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for BU(EQUIPOISE); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is BU(EQUIPOISE) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "BU(EQUIPOISE): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=BU",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "BU(EQUIPOISE): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=BU",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "BU(EQUIPOISE): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "cabergoline",
    "title": "Cabergoline",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Cabergoline guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cabergoline appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Cabergoline; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Cabergoline appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cabergoline: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cabergoline",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cabergoline: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cabergoline",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cabergoline: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "cagrilintide",
    "title": "Cagrilintide",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Cagrilintide guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cagrilintide appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Cagrilintide; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Cagrilintide appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cagrilintide: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cagrilintide",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cagrilintide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cagrilintide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cagrilintide: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "cagrilintide-5mg-plus-semaglutide-5mg-blend",
    "title": "Cagrilintide 5mg+Semaglutide 5mg Blend",
    "aliases": [],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Cagrilintide 5mg+Semaglutide 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cagrilintide 5mg+Semaglutide 5mg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Cagrilintide 5mg+Semaglutide 5mg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Cagrilintide 5mg+Semaglutide 5mg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cagrilintide 5mg+Semaglutide 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cagrilintide%205mg%2BSemaglutide%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cagrilintide 5mg+Semaglutide 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cagrilintide%205mg%2BSemaglutide%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cagrilintide 5mg+Semaglutide 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "cagrisema",
    "title": "CagriSema",
    "aliases": [
      "Cagrilintide + Semaglutide"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CagriSema guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. CagriSema is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Investigational combination studies use stepwise weekly escalation schedules and protocol-specific caps. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for CagriSema in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CagriSema: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=CagriSema",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CagriSema: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=CagriSema",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CagriSema: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CagriSema",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "CagriSema: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CagriSema+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "calcium",
    "title": "Calcium",
    "aliases": [
      "Ca"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Calcium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Calcium guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize calcium dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Calcium in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Calcium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Calcium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Calcium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Calcium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Calcium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "cerebrolysin",
    "title": "Cerebrolysin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Cerebrolysin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Cerebrolysin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Cerebrolysin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Cerebrolysin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Cerebrolysin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Cerebrolysin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Cerebrolysin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Cerebrolysin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Cerebrolysin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "chloride",
    "title": "Chloride",
    "aliases": [
      "Cl"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Chloride guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Chloride guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize chloride dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Chloride in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Chloride: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/list-all/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Chloride: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Chloride",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Chloride: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Chloride+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "chromium",
    "title": "Chromium",
    "aliases": [
      "Cr"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Chromium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Chromium guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize chromium dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Chromium in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Chromium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Chromium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Chromium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Chromium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Chromium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Chromium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "cjc-1295",
    "title": "CJC-1295",
    "aliases": [
      "CJC1295 (no DAC)",
      "CJC-1295 Without DAC"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CJC-1295 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. CJC-1295 is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Common research-use patterns report 100-300 mcg once or multiple times daily depending on stack design. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for CJC-1295 in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CJC-1295: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CJC-1295: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=CJC-1295",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CJC-1295: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "CJC-1295: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "cjc-1295-without-dac-5mg-plus-ipa-5mg-blend",
    "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CJC-1295 without DAC 5mg + IPA 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "CJC-1295 without DAC 5mg + IPA 5mg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for CJC-1295 without DAC 5mg + IPA 5mg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is CJC-1295 without DAC 5mg + IPA 5mg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295%20without%20DAC%205mg%20%2B%20IPA%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295%20without%20DAC%205mg%20%2B%20IPA%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CJC-1295 without DAC 5mg + IPA 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "cjc-dac",
    "title": "CJC-1295 DAC",
    "aliases": [
      "CJC-DAC",
      "CJC-1295 With DAC"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CJC-1295 DAC guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. CJC-1295 DAC is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Longer-acting DAC protocols often report 1-2 mg weekly with periodic cycle breaks. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for CJC-1295 DAC in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CJC-1295 DAC: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295%20DAC",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CJC-1295 DAC: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=CJC-1295%20DAC",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CJC-1295 DAC: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CJC-1295%20DAC",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "CJC-1295 DAC: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295%20DAC+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "clenbuterol",
    "title": "CLENBUTEROL",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "CLENBUTEROL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "CLENBUTEROL appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for CLENBUTEROL; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is CLENBUTEROL appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "CLENBUTEROL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=CLENBUTEROL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "CLENBUTEROL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=CLENBUTEROL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "CLENBUTEROL: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "clomid",
    "title": "Clomid",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Clomid guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Clomid appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Clomid; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Clomid appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Clomid: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Clomid",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Clomid: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Clomid",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Clomid: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "cock-bombs",
    "title": "COCK BOMBS",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "COCK BOMBS guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "COCK BOMBS appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for COCK BOMBS; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is COCK BOMBS appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "COCK BOMBS: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=COCK%20BOMBS",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "COCK BOMBS: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=COCK%20BOMBS",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "COCK BOMBS: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "copper",
    "title": "Copper",
    "aliases": [
      "Cu"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Copper guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Copper guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize copper dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Copper in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Copper: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Copper-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Copper: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Copper",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Copper: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Copper+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "d320",
    "title": "D320",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "D320 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "D320 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for D320; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is D320 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "D320: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=D320",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "D320: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=D320",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "D320: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "danuglipron",
    "title": "Danuglipron",
    "aliases": [
      "PF-06882961"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Danuglipron guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Danuglipron is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Investigational oral dosing has been studied in daily and twice-daily formats with dose-limiting GI effects. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Danuglipron in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Danuglipron: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Danuglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Danuglipron: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Danuglipron",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Danuglipron: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Danuglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Danuglipron: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Danuglipron+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "deca-nd",
    "title": "DECA(ND)",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DECA(ND) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DECA(ND) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for DECA(ND); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DECA(ND) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DECA(ND): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DECA",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DECA(ND): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DECA",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DECA(ND): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "dermorphin",
    "title": "Dermorphin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Dermorphin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Dermorphin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Dermorphin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Dermorphin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dermorphin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dermorphin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dermorphin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dermorphin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dermorphin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "dhb-1-test-cyp",
    "title": "DHB(1-Test Cyp)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DHB(1-Test Cyp) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DHB(1-Test Cyp) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for DHB(1-Test Cyp); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DHB(1-Test Cyp) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DHB(1-Test Cyp): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DHB",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DHB(1-Test Cyp): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DHB",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DHB(1-Test Cyp): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "dht-stanolone",
    "title": "DHT (Stanolone)",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DHT (Stanolone) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DHT (Stanolone) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for DHT (Stanolone); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DHT (Stanolone) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DHT (Stanolone): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DHT",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DHT (Stanolone): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DHT",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DHT (Stanolone): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "dianabol",
    "title": "DIANABOL",
    "aliases": [
      "DIANABOL(Methandrostenolone)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DIANABOL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DIANABOL appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for DIANABOL; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DIANABOL appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DIANABOL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DIANABOL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DIANABOL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DIANABOL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DIANABOL: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "dihexa",
    "title": "Dihexa",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Dihexa guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Dihexa appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Dihexa; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Dihexa appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dihexa: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dihexa",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dihexa: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dihexa",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dihexa: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "dnp",
    "title": "DNP",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DNP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DNP appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for DNP; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DNP appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DNP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DNP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DNP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DNP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DNP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "dsip",
    "title": "DSIP",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "DSIP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "DSIP appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for DSIP; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is DSIP appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "DSIP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=DSIP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "DSIP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=DSIP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "DSIP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "dulaglutide",
    "title": "Dulaglutide",
    "aliases": [
      "Trulicity"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Dulaglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Dulaglutide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Label pathways generally begin at 0.75 mg weekly and may increase to 1.5, 3.0, and 4.5 mg as tolerated. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Weekly adherence with exact injection-day drift tracking.",
      "Nausea, reflux, bowel-pattern, and meal-size tolerance logs.",
      "Weight trend slope and appetite-return timing across weekly curve."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Dulaglutide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dulaglutide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Dulaglutide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dulaglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dulaglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dulaglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dulaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Dulaglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dulaglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "dutasteride",
    "title": "Dutasteride",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Dutasteride guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Dutasteride appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Dutasteride; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Dutasteride appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Dutasteride: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Dutasteride",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Dutasteride: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Dutasteride",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Dutasteride: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ecnoglutide",
    "title": "Ecnoglutide",
    "aliases": [
      "XW003"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ecnoglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Ecnoglutide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Investigational weekly schedules in trials use protocol-controlled escalation with exposure monitoring. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Ecnoglutide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ecnoglutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Ecnoglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ecnoglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ecnoglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ecnoglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ecnoglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Ecnoglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ecnoglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "efpeglenatide",
    "title": "Efpeglenatide",
    "aliases": [
      "AMG 133 (historical context)"
    ],
    "category": "GLP-1",
    "status": "discontinued",
    "statusLabel": "Discontinued/Legacy",
    "metaDescription": "Efpeglenatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Efpeglenatide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Prior trial programs evaluated weekly 4-6 mg dosing tiers; active program availability varies by region. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Weekly adherence with exact injection-day drift tracking.",
      "Nausea, reflux, bowel-pattern, and meal-size tolerance logs.",
      "Weight trend slope and appetite-return timing across weekly curve."
    ],
    "safetyFlags": [
      "Discontinued or region-limited compounds may have constrained safety/quality oversight by market.",
      "Verify product legitimacy and clinician rationale before any use discussion.",
      "Escalate adverse effects quickly because support infrastructure may be inconsistent."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Efpeglenatide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Efpeglenatide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Efpeglenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Efpeglenatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Efpeglenatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Efpeglenatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Efpeglenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Efpeglenatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Efpeglenatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "epithalon",
    "title": "Epithalon",
    "aliases": [
      "Epitalon"
    ],
    "category": "Anti-Aging Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Epithalon guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Epithalon is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Cycle-based protocols often cite 5-10 mg daily for short blocks with long off-cycles. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Epithalon in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Epithalon: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Epithalon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Epithalon: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Epithalon",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Epithalon: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Epithalon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Epithalon: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Epithalon+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "epo",
    "title": "EPO",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "EPO guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "EPO appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for EPO; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is EPO appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "EPO: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=EPO",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "EPO: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=EPO",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "EPO: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "estradial-cypionate",
    "title": "Estradial Cypionate",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Estradial Cypionate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Estradial Cypionate appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Estradial Cypionate; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Estradial Cypionate appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Estradial Cypionate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Estradial%20Cypionate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Estradial Cypionate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Estradial%20Cypionate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Estradial Cypionate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "exenatide",
    "title": "Exenatide",
    "aliases": [
      "Byetta",
      "Bydureon"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Exenatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Exenatide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Immediate-release labeling uses 5-10 mcg twice daily, while extended-release forms use 2 mg weekly. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Weekly adherence with exact injection-day drift tracking.",
      "Nausea, reflux, bowel-pattern, and meal-size tolerance logs.",
      "Weight trend slope and appetite-return timing across weekly curve."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Exenatide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Exenatide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Exenatide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Exenatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Exenatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Exenatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Exenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Exenatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Exenatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "finasteride",
    "title": "Finasteride",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Finasteride guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Finasteride appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Finasteride; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Finasteride appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Finasteride: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Finasteride",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Finasteride: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Finasteride",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Finasteride: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "flibanserin",
    "title": "Flibanserin",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Flibanserin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Flibanserin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Flibanserin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Flibanserin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Flibanserin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Flibanserin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Flibanserin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Flibanserin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Flibanserin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "fluoxymesterone-halotestin",
    "title": "Fluoxymesterone(Halotestin)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Fluoxymesterone(Halotestin) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Fluoxymesterone(Halotestin) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Fluoxymesterone(Halotestin); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Fluoxymesterone(Halotestin) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Fluoxymesterone(Halotestin): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Fluoxymesterone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Fluoxymesterone(Halotestin): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Fluoxymesterone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Fluoxymesterone(Halotestin): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "follistatin",
    "title": "Follistatin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Follistatin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Follistatin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Follistatin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Follistatin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Follistatin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Follistatin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Follistatin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Follistatin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Follistatin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "foxo4",
    "title": "FOXO4",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "FOXO4 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "FOXO4 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for FOXO4; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is FOXO4 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "FOXO4: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=FOXO4",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "FOXO4: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=FOXO4",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "FOXO4: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "fragment-176-191",
    "title": "Fragment 176-191",
    "aliases": [
      "HGH Fragment 176-191"
    ],
    "category": "Fat Loss Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Fragment 176-191 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Fragment 176-191 is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Non-labeled protocols commonly report 250-750 mcg once or twice daily in fasted periods. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Fragment 176-191 in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Fragment 176-191: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Fragment%20176-191",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Fragment 176-191: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Fragment%20176-191",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Fragment 176-191: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Fragment%20176-191",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Fragment 176-191: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Fragment%20176-191+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "gaz",
    "title": "GAZ",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GAZ guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GAZ appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for GAZ; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is GAZ appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GAZ: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GAZ",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GAZ: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GAZ",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GAZ: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ghk-cu",
    "title": "GHK-CU",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHK-CU guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GHK-CU appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for GHK-CU; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is GHK-CU appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHK-CU: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHK-CU",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHK-CU: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHK-CU",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHK-CU: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ghrp-2",
    "title": "GHRP-2",
    "aliases": [
      "Growth Hormone Releasing Peptide-2"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-2 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. GHRP-2 is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Research-use ranges often cite 100-300 mcg per dose, up to 2-3 administrations daily. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for GHRP-2 in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-2: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-2",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-2: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=GHRP-2",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-2: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-2",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "GHRP-2: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-2+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "ghrp-2-acetate",
    "title": "GHRP-2 Acetate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-2 Acetate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GHRP-2 Acetate appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for GHRP-2 Acetate; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is GHRP-2 Acetate appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-2 Acetate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-2%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-2 Acetate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-2%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-2 Acetate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ghrp-6",
    "title": "GHRP-6",
    "aliases": [
      "Growth Hormone Releasing Peptide-6"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-6 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. GHRP-6 is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Common protocols report 100-300 mcg per administration with hunger effects as a limiting factor. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for GHRP-6 in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-6: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-6",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-6: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=GHRP-6",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-6: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-6",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "GHRP-6: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-6+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "ghrp-6-acetate",
    "title": "GHRP-6 Acetate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GHRP-6 Acetate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GHRP-6 Acetate appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for GHRP-6 Acetate; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is GHRP-6 Acetate appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GHRP-6 Acetate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-6%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GHRP-6 Acetate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHRP-6%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GHRP-6 Acetate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "glow-ghk-cu-50mg-plus-tb500-10mg-plus-bpc157-10mg-blend",
    "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for (GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is (GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "(GLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "glutathione",
    "title": "Glutathione",
    "aliases": [
      "GSH"
    ],
    "category": "Antioxidant",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Glutathione guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Glutathione is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Common injectable support protocols use 200-1000 mg per dose one to three times weekly. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Compounded/supportive products can vary by formulation and concentration.",
      "Verify storage, sterility, and route-specific administration safety before use.",
      "Escalate persistent injection-site reactions, systemic symptoms, or intolerance."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Glutathione in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Glutathione: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Glutathione&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Glutathione: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Glutathione",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Glutathione: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Glutathione",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Glutathione: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Glutathione+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "gonadorelin",
    "title": "Gonadorelin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Gonadorelin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Gonadorelin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Gonadorelin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Compounded or supportive products can vary by concentration and handling requirements.",
      "Verify sterile technique, storage conditions, and route-specific safety.",
      "Escalate persistent intolerance, reactions, or contamination concerns promptly."
    ],
    "providerQuestions": [
      "Is Gonadorelin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Gonadorelin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Gonadorelin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Gonadorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Gonadorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Gonadorelin: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Gonadorelin",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "gw-501516-cardarine",
    "title": "GW-501516(Cardarine)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "GW-501516(Cardarine) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "GW-501516(Cardarine) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for GW-501516(Cardarine); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is GW-501516(Cardarine) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "GW-501516(Cardarine): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GW-501516",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "GW-501516(Cardarine): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GW-501516",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "GW-501516(Cardarine): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "hcg",
    "title": "Human Chorionic Gonadotropin (HCG)",
    "aliases": [
      "Pregnyl",
      "Ovidrel",
      "HCG"
    ],
    "category": "Hormone",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Human Chorionic Gonadotropin (HCG) guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Human Chorionic Gonadotropin (HCG) is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Depending on indication, protocols vary widely; TRT-support workflows frequently use 250-1000 IU 2-3 times weekly. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Human Chorionic Gonadotropin (HCG) in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Human Chorionic Gonadotropin (HCG): FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Human%20Chorionic%20Gonadotropin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Human Chorionic Gonadotropin (HCG): DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Human%20Chorionic%20Gonadotropin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Human Chorionic Gonadotropin (HCG): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Human%20Chorionic%20Gonadotropin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Human Chorionic Gonadotropin (HCG): PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Human%20Chorionic%20Gonadotropin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "hexarelin",
    "title": "Hexarelin",
    "aliases": [
      "Examorelin"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Hexarelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Hexarelin is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Reported research protocols often use 100-200 mcg per administration with cycle limits to reduce desensitization. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Hexarelin in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Hexarelin: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Hexarelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Hexarelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Hexarelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Hexarelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Hexarelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Hexarelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Hexarelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "hgh-191aa-somatropin",
    "title": "HGH 191AA (Somatropin)",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "HGH 191AA (Somatropin) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "HGH 191AA (Somatropin) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for HGH 191AA (Somatropin); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is HGH 191AA (Somatropin) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "HGH 191AA (Somatropin): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=HGH%20191AA",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "HGH 191AA (Somatropin): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=HGH%20191AA",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "HGH 191AA (Somatropin): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "hhb",
    "title": "HHB",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "HHB guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "HHB appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for HHB; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is HHB appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "HHB: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=HHB",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "HHB: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=HHB",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "HHB: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "hmg",
    "title": "HMG",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "HMG guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "HMG appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for HMG; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is HMG appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "HMG: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=HMG",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "HMG: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=HMG",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "HMG: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "hyaluronic-acid",
    "title": "Hyaluronic acid",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Hyaluronic acid guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Hyaluronic acid appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Hyaluronic acid; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Compounded or supportive products can vary by concentration and handling requirements.",
      "Verify sterile technique, storage conditions, and route-specific safety.",
      "Escalate persistent intolerance, reactions, or contamination concerns promptly."
    ],
    "providerQuestions": [
      "Is Hyaluronic acid appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Hyaluronic acid: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Hyaluronic%20acid",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Hyaluronic acid: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Hyaluronic%20acid",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Hyaluronic acid: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Hyaluronic%20acid",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "igf-1lr3",
    "title": "IGF-1LR3",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "IGF-1LR3 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "IGF-1LR3 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for IGF-1LR3; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is IGF-1LR3 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "IGF-1LR3: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=IGF-1LR3",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "IGF-1LR3: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=IGF-1LR3",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "IGF-1LR3: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "igf-des",
    "title": "IGF-DES",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "IGF-DES guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "IGF-DES appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for IGF-DES; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is IGF-DES appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "IGF-DES: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=IGF-DES",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "IGF-DES: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=IGF-DES",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "IGF-DES: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "insulin",
    "title": "Insulin",
    "aliases": [
      "Humalog",
      "Novolog",
      "Lantus",
      "Tresiba"
    ],
    "category": "Insulin",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Insulin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Insulin is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Insulin is individualized by type, glucose targets, and carbohydrate patterns; dosing requires clinician-directed plans. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Glucose response around meals and corrections.",
      "Hypoglycemia timing, severity, and rescue actions.",
      "Injection site rotation and insulin-on-board context."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Insulin in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Insulin: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Insulin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Insulin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Insulin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Insulin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Insulin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Insulin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Insulin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "iodine",
    "title": "Iodine",
    "aliases": [
      "I"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Iodine guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Iodine guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize iodine dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Iodine in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Iodine: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Iodine-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Iodine: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Iodine",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Iodine: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Iodine+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "ipamorelin",
    "title": "Ipamorelin",
    "aliases": [
      "IPA"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ipamorelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Ipamorelin is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Clinic protocols frequently cite 100-300 mcg once to three times daily, often paired with CJC variants. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Ipamorelin in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ipamorelin: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Ipamorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ipamorelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ipamorelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ipamorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ipamorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Ipamorelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ipamorelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "iron",
    "title": "Iron",
    "aliases": [
      "Fe"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Iron guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Iron guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize iron dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Iron in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Iron: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Iron: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Iron",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Iron: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Iron+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "isotretinoin",
    "title": "isotretinoin",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "isotretinoin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "isotretinoin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for isotretinoin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is isotretinoin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "isotretinoin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=isotretinoin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "isotretinoin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=isotretinoin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "isotretinoin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ivermectin",
    "title": "Ivermectin",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ivermectin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Ivermectin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Ivermectin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Ivermectin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ivermectin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ivermectin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ivermectin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ivermectin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ivermectin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "kisspeptin-10",
    "title": "KissPeptin-10",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "KissPeptin-10 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "KissPeptin-10 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for KissPeptin-10; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is KissPeptin-10 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "KissPeptin-10: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=KissPeptin-10",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "KissPeptin-10: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=KissPeptin-10",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "KissPeptin-10: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "klow-ghk-cu-50mg-plus-tb500-10mg-plus-bpc157-10mg-plus-kpv-10mg-blend",
    "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for (KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is (KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%2BKPV%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=GHK-CU%2050mg%2BTB500%2010mg%2BBPC157%2010mg%2BKPV%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "(KLOW)GHK-CU 50mg+TB500 10mg+BPC157 10mg+KPV 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "kpv",
    "title": "KPV",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "KPV guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "KPV appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for KPV; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is KPV appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "KPV: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=KPV",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "KPV: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=KPV",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "KPV: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "l-carnitine",
    "title": "L-Carnitine",
    "aliases": [
      "Levocarnitine"
    ],
    "category": "Amino Acid",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "L-Carnitine guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. L-Carnitine is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Injectable support use commonly ranges from 500-2000 mg daily or several times weekly. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Compounded/supportive products can vary by formulation and concentration.",
      "Verify storage, sterility, and route-specific administration safety before use.",
      "Escalate persistent injection-site reactions, systemic symptoms, or intolerance."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for L-Carnitine in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "L-Carnitine: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:L-Carnitine&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "L-Carnitine: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=L-Carnitine",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "L-Carnitine: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=L-Carnitine",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "L-Carnitine: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=L-Carnitine+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "lc425",
    "title": "LC425",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC425 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LC425 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for LC425; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC425 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC425: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC425",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC425: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC425",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC425: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "lc500",
    "title": "LC500",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC500 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LC500 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for LC500; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC500 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC500: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC500",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC500: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC500",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC500: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "lc526",
    "title": "LC526",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC526 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LC526 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for LC526; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC526 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC526: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC526",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC526: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC526",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC526: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "lc553",
    "title": "LC553",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LC553 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LC553 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for LC553; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LC553 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LC553: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LC553",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LC553: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LC553",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LC553: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "letrozole",
    "title": "Letrozole",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Letrozole guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Letrozole appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Letrozole; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Letrozole appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Letrozole: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Letrozole",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Letrozole: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Letrozole",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Letrozole: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "lgd-4033-ligandrol",
    "title": "LGD-4033(Ligandrol)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LGD-4033(Ligandrol) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LGD-4033(Ligandrol) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for LGD-4033(Ligandrol); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LGD-4033(Ligandrol) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LGD-4033(Ligandrol): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LGD-4033",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LGD-4033(Ligandrol): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LGD-4033",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LGD-4033(Ligandrol): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "lipo-c-120mg",
    "title": "Lipo-C 120mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Lipo-C 120mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Lipo-C 120mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Lipo-C 120mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Compounded or supportive products can vary by concentration and handling requirements.",
      "Verify sterile technique, storage conditions, and route-specific safety.",
      "Escalate persistent intolerance, reactions, or contamination concerns promptly."
    ],
    "providerQuestions": [
      "Is Lipo-C 120mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Lipo-C 120mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Lipo-C%20120mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Lipo-C 120mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Lipo-C%20120mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Lipo-C 120mg: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Lipo-C%20120mg",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "lipo-c-216mg",
    "title": "Lipo-C 216mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Lipo-C 216mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Lipo-C 216mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Lipo-C 216mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Compounded or supportive products can vary by concentration and handling requirements.",
      "Verify sterile technique, storage conditions, and route-specific safety.",
      "Escalate persistent intolerance, reactions, or contamination concerns promptly."
    ],
    "providerQuestions": [
      "Is Lipo-C 216mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Lipo-C 216mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Lipo-C%20216mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Lipo-C 216mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Lipo-C%20216mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Lipo-C 216mg: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Lipo-C%20216mg",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "liraglutide",
    "title": "Liraglutide",
    "aliases": [
      "Victoza",
      "Saxenda"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Liraglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Liraglutide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Label titration usually starts at 0.6 mg daily and steps to 1.2, 1.8, or 3.0 mg by indication. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Weekly adherence with exact injection-day drift tracking.",
      "Nausea, reflux, bowel-pattern, and meal-size tolerance logs.",
      "Weight trend slope and appetite-return timing across weekly curve."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Liraglutide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Liraglutide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Liraglutide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Liraglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Liraglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Liraglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Liraglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Liraglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Liraglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "lixisenatide",
    "title": "Lixisenatide",
    "aliases": [
      "Adlyxin",
      "Lyxumia"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Lixisenatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Lixisenatide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Labeled dosing commonly starts at 10 mcg daily for 14 days then increases to 20 mcg daily. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Weekly adherence with exact injection-day drift tracking.",
      "Nausea, reflux, bowel-pattern, and meal-size tolerance logs.",
      "Weight trend slope and appetite-return timing across weekly curve."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Lixisenatide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Lixisenatide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Lixisenatide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Lixisenatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lixisenatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Lixisenatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Lixisenatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Lixisenatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Lixisenatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "ll37",
    "title": "LL37",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LL37 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LL37 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for LL37; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LL37 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LL37: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LL37",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LL37: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LL37",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LL37: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "lmx",
    "title": "LMX",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "LMX guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "LMX appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for LMX; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is LMX appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "LMX: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=LMX",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "LMX: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=LMX",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "LMX: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "magnesium",
    "title": "Magnesium",
    "aliases": [
      "Mg"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Magnesium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Magnesium guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize magnesium dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Magnesium in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Magnesium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Magnesium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Magnesium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Magnesium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Magnesium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "manganese",
    "title": "Manganese",
    "aliases": [
      "Mn"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Manganese guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Manganese guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize manganese dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Manganese in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Manganese: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Manganese-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Manganese: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Manganese",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Manganese: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Manganese+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "mast-blend-200mg",
    "title": "MAST Blend 200mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MAST Blend 200mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MAST Blend 200mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for MAST Blend 200mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MAST Blend 200mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MAST Blend 200mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MAST%20Blend%20200mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MAST Blend 200mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MAST%20Blend%20200mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MAST Blend 200mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "mast-e-de",
    "title": "Mast E(DE)",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Mast E(DE) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Mast E(DE) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Mast E(DE); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Mast E(DE) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Mast E(DE): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Mast%20E",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Mast E(DE): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Mast%20E",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Mast E(DE): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "mast-p-dp",
    "title": "Mast P(DP)",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Mast P(DP) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Mast P(DP) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Mast P(DP); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Mast P(DP) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Mast P(DP): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Mast%20P",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Mast P(DP): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Mast%20P",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Mast P(DP): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "mazdutide",
    "title": "Mazdutide",
    "aliases": [
      "IBI362"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Mazdutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Mazdutide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Investigational weekly regimens use staged escalation protocols with trial-specific maximum doses. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Mazdutide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Mazdutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Mazdutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Mazdutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Mazdutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Mazdutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Mazdutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Mazdutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Mazdutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "melanotan-2",
    "title": "Melanotan II",
    "aliases": [
      "MT2"
    ],
    "category": "Other Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Melanotan II guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Melanotan II is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Reported protocols often begin around 250 mcg and titrate toward 500-1000 mcg based on tolerance. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Melanotan II in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Melanotan II: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Melanotan%20II",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Melanotan II: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Melanotan%20II",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Melanotan II: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Melanotan%20II",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Melanotan II: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Melanotan%20II+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "melatonin",
    "title": "Melatonin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "Melatonin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Melatonin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Melatonin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Compounded or supportive products can vary by concentration and handling requirements.",
      "Verify sterile technique, storage conditions, and route-specific safety.",
      "Escalate persistent intolerance, reactions, or contamination concerns promptly."
    ],
    "providerQuestions": [
      "Is Melatonin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Melatonin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Melatonin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Melatonin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Melatonin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Melatonin: MedlinePlus safety and interaction context",
        "url": "https://medlineplus.gov/?query=Melatonin",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ment-trestolone-acetate",
    "title": "MENT (Trestolone acetate)",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MENT (Trestolone acetate) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MENT (Trestolone acetate) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for MENT (Trestolone acetate); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MENT (Trestolone acetate) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MENT (Trestolone acetate): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MENT",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MENT (Trestolone acetate): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MENT",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MENT (Trestolone acetate): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "metformin",
    "title": "Metformin",
    "aliases": [
      "Glucophage",
      "Glumetza"
    ],
    "category": "Metformin",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Metformin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Metformin is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Typical clinical pathways start at 500 mg once daily and titrate in 500 mg increments toward 1500-2000 mg/day. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Meal timing versus GI symptoms and adherence.",
      "Fasting glucose context with consistent measurement windows.",
      "Renal-lab follow-up reminders and tolerance over titration windows."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Metformin in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Metformin: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Metformin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Metformin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Metformin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Metformin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Metformin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Metformin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Metformin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "methenolone-acetate-primobolan",
    "title": "Methenolone Acetate(Primobolan)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Methenolone Acetate(Primobolan) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Methenolone Acetate(Primobolan) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Methenolone Acetate(Primobolan); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Methenolone Acetate(Primobolan) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Methenolone Acetate(Primobolan): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Methenolone%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Methenolone Acetate(Primobolan): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Methenolone%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Methenolone Acetate(Primobolan): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "methylene-blue",
    "title": "Methylene Blue",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Methylene Blue guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Methylene Blue appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Methylene Blue; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Methylene Blue appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Methylene Blue: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Methylene%20Blue",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Methylene Blue: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Methylene%20Blue",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Methylene Blue: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "methylstenbolone",
    "title": "Methylstenbolone",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Methylstenbolone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Methylstenbolone appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Methylstenbolone; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Methylstenbolone appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Methylstenbolone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Methylstenbolone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Methylstenbolone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Methylstenbolone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Methylstenbolone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "metribolone",
    "title": "Metribolone",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Metribolone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Metribolone appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Metribolone; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Metribolone appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Metribolone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Metribolone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Metribolone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Metribolone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Metribolone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "mgf",
    "title": "MGF",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MGF guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MGF appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for MGF; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MGF appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MGF: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MGF",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MGF: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MGF",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MGF: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "mic",
    "title": "MIC Injection",
    "aliases": [
      "Lipotropic Injection",
      "Lipo-B"
    ],
    "category": "Weight Loss Blend",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "MIC Injection guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. MIC Injection is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Clinic programs commonly use 1-2 mL weekly or twice weekly depending on concentration and tolerability. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Compounded/supportive products can vary by formulation and concentration.",
      "Verify storage, sterility, and route-specific administration safety before use.",
      "Escalate persistent injection-site reactions, systemic symptoms, or intolerance."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for MIC Injection in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MIC Injection: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:MIC%20Injection&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MIC Injection: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=MIC%20Injection",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MIC Injection: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MIC%20Injection",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "MIC Injection: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MIC%20Injection+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "minoxidil",
    "title": "Minoxidil",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Minoxidil guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Minoxidil appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Minoxidil; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Minoxidil appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Minoxidil: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Minoxidil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Minoxidil: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Minoxidil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Minoxidil: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "mk-677-ibutamoren",
    "title": "MK-677(Ibutamoren)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MK-677(Ibutamoren) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MK-677(Ibutamoren) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for MK-677(Ibutamoren); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MK-677(Ibutamoren) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MK-677(Ibutamoren): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MK-677",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MK-677(Ibutamoren): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MK-677",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MK-677(Ibutamoren): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "molybdenum",
    "title": "Molybdenum",
    "aliases": [
      "Mo"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Molybdenum guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Molybdenum guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize molybdenum dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Molybdenum in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Molybdenum: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Molybdenum-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Molybdenum: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Molybdenum",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Molybdenum: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Molybdenum+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "mots-c",
    "title": "MOTS-C",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MOTS-C guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MOTS-C appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for MOTS-C; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MOTS-C appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MOTS-C: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MOTS-C",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MOTS-C: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MOTS-C",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MOTS-C: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "mt-1",
    "title": "MT-1",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MT-1 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MT-1 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for MT-1; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MT-1 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MT-1: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MT-1",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MT-1: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MT-1",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MT-1: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "mt-2",
    "title": "MT-2",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "MT-2 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "MT-2 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for MT-2; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is MT-2 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "MT-2: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=MT-2",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "MT-2: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=MT-2",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "MT-2: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "n-acetyl-epitalon-amidate",
    "title": "N-Acetyl Epitalon Amidate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "N-Acetyl Epitalon Amidate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "N-Acetyl Epitalon Amidate appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for N-Acetyl Epitalon Amidate; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is N-Acetyl Epitalon Amidate appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "N-Acetyl Epitalon Amidate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=N-Acetyl%20Epitalon%20Amidate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "N-Acetyl Epitalon Amidate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=N-Acetyl%20Epitalon%20Amidate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "N-Acetyl Epitalon Amidate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "nad-plus",
    "title": "NAD+",
    "aliases": [
      "Nicotinamide Adenine Dinucleotide",
      "NAD"
    ],
    "category": "Coenzyme",
    "status": "support",
    "statusLabel": "Supportive Therapy",
    "metaDescription": "NAD+ guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. NAD+ is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Support protocols often use 50-200 mg per injection one to three times weekly, with slow administration emphasized. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Compounded/supportive products can vary by formulation and concentration.",
      "Verify storage, sterility, and route-specific administration safety before use.",
      "Escalate persistent injection-site reactions, systemic symptoms, or intolerance."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for NAD+ in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "NAD+: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:NAD%2B&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "NAD+: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=NAD%2B",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "NAD+: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=NAD%2B",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "NAD+: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=NAD%2B+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "nandromix-300mg",
    "title": "NANDROMIX 300mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "NANDROMIX 300mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "NANDROMIX 300mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for NANDROMIX 300mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is NANDROMIX 300mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "NANDROMIX 300mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=NANDROMIX%20300mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "NANDROMIX 300mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=NANDROMIX%20300mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "NANDROMIX 300mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "npp",
    "title": "NPP",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "NPP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "NPP appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for NPP; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is NPP appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "NPP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=NPP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "NPP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=NPP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "NPP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "orforglipron",
    "title": "Orforglipron",
    "aliases": [
      "LY3502970"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Orforglipron guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Orforglipron is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Investigational oral regimens in development use daily fixed-dose schedules with protocol-based escalation. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Orforglipron in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Orforglipron: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Orforglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Orforglipron: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Orforglipron",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Orforglipron: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Orforglipron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Orforglipron: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Orforglipron+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "ostarine-mk-2866",
    "title": "Ostarine / MK-2866",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Ostarine / MK-2866 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Ostarine / MK-2866 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Ostarine / MK-2866; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Ostarine / MK-2866 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Ostarine / MK-2866: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Ostarine%20%2F%20MK-2866",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Ostarine / MK-2866: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Ostarine%20%2F%20MK-2866",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Ostarine / MK-2866: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "oxytocin-acetate",
    "title": "Oxytocin Acetate",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Oxytocin Acetate guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Oxytocin Acetate appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Oxytocin Acetate; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Oxytocin Acetate appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Oxytocin Acetate: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Oxytocin%20Acetate",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Oxytocin Acetate: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Oxytocin%20Acetate",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Oxytocin Acetate: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "p21",
    "title": "P21",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "P21 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "P21 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for P21; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is P21 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "P21: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=P21",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "P21: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=P21",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "P21: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "pe-22-28",
    "title": "PE 22-28",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "PE 22-28 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "PE 22-28 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for PE 22-28; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is PE 22-28 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PE 22-28: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PE%2022-28",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PE 22-28: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PE%2022-28",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PE 22-28: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "peg-mgf",
    "title": "PEG MGF",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "PEG MGF guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "PEG MGF appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for PEG MGF; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is PEG MGF appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PEG MGF: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PEG%20MGF",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PEG MGF: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PEG%20MGF",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PEG MGF: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "phosphorus",
    "title": "Phosphorus",
    "aliases": [
      "P"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Phosphorus guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Phosphorus guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize phosphorus dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Phosphorus in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Phosphorus: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Phosphorus-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Phosphorus: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Phosphorus",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Phosphorus: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Phosphorus+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "pinealon",
    "title": "Pinealon",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Pinealon guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Pinealon appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Pinealon; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Pinealon appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Pinealon: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Pinealon",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Pinealon: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Pinealon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Pinealon: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "pnc-27",
    "title": "PNC 27",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "PNC 27 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "PNC 27 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for PNC 27; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is PNC 27 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PNC 27: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PNC%2027",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PNC 27: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PNC%2027",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PNC 27: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "potassium",
    "title": "Potassium",
    "aliases": [
      "K"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Potassium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Potassium guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize potassium dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Potassium in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Potassium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Potassium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Potassium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Potassium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Potassium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Potassium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "prednisone",
    "title": "Prednisone",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Prednisone guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Prednisone appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Prednisone; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Prednisone appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Prednisone: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Prednisone",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Prednisone: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Prednisone",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Prednisone: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "primobolan-e",
    "title": "Primobolan E",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Primobolan E guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Primobolan E appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Primobolan E; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Primobolan E appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Primobolan E: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Primobolan%20E",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Primobolan E: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Primobolan%20E",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Primobolan E: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "proviron",
    "title": "Proviron",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Proviron guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Proviron appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Proviron; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Proviron appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Proviron: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Proviron",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Proviron: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Proviron",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Proviron: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "pt-141",
    "title": "PT-141 (Bremelanotide)",
    "aliases": [
      "Vyleesi",
      "PT-141"
    ],
    "category": "Other Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "PT-141 (Bremelanotide) guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. PT-141 (Bremelanotide) is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Approved HSDD labeling uses on-demand administration with limits on dose frequency per 24-hour and monthly windows. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for PT-141 (Bremelanotide) in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "PT-141 (Bremelanotide): FDA/openFDA labeling and safety records",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "PT-141 (Bremelanotide): DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=PT-141",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "PT-141 (Bremelanotide): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=PT-141",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "PT-141 (Bremelanotide): PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=PT-141+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "rad140",
    "title": "RAD140",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "RAD140 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "RAD140 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for RAD140; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is RAD140 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "RAD140: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=RAD140",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "RAD140: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=RAD140",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "RAD140: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "retatrutide",
    "title": "Retatrutide",
    "aliases": [
      "LY3437943"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Retatrutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Retatrutide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Phase studies use weekly dose-escalation cohorts with protocol-defined ceilings and adverse-event monitoring. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Retatrutide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Retatrutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Retatrutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Retatrutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Retatrutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Retatrutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Retatrutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Retatrutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Retatrutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "retatrutide-5mg-plus-cagrilintide-5mg-blend",
    "title": "Retatrutide 5mg+Cagrilintide 5mg Blend",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Retatrutide 5mg+Cagrilintide 5mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Retatrutide 5mg+Cagrilintide 5mg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Retatrutide 5mg+Cagrilintide 5mg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Retatrutide 5mg+Cagrilintide 5mg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Retatrutide 5mg+Cagrilintide 5mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Retatrutide%205mg%2BCagrilintide%205mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Retatrutide 5mg+Cagrilintide 5mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Retatrutide%205mg%2BCagrilintide%205mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Retatrutide 5mg+Cagrilintide 5mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ripex",
    "title": "RIPEX",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "RIPEX guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "RIPEX appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for RIPEX; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is RIPEX appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "RIPEX: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=RIPEX",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "RIPEX: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=RIPEX",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "RIPEX: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "rp226",
    "title": "RP226",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "RP226 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "RP226 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for RP226; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is RP226 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "RP226: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=RP226",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "RP226: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=RP226",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "RP226: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "salbutamol",
    "title": "SALBUTAMOL",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SALBUTAMOL guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SALBUTAMOL appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for SALBUTAMOL; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SALBUTAMOL appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SALBUTAMOL: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SALBUTAMOL",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SALBUTAMOL: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SALBUTAMOL",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SALBUTAMOL: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "selank",
    "title": "Selank",
    "aliases": [
      "Tuftsin Analog"
    ],
    "category": "Nootropic Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Selank guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Selank is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Research-use schedules commonly report 250-750 mcg once or twice daily by route. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Selank in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Selank: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Selank",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Selank: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Selank",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Selank: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Selank",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Selank: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Selank+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "selank-10mg-plus-semax-10mg-blend",
    "title": "Selank 10mg + Semax 10mg Blend",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Selank 10mg + Semax 10mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Selank 10mg + Semax 10mg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Selank 10mg + Semax 10mg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Selank 10mg + Semax 10mg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Selank 10mg + Semax 10mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Selank%2010mg%20%2B%20Semax%2010mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Selank 10mg + Semax 10mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Selank%2010mg%20%2B%20Semax%2010mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Selank 10mg + Semax 10mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "selenium",
    "title": "Selenium",
    "aliases": [
      "Se"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Selenium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Selenium guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize selenium dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Selenium in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Selenium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Selenium-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Selenium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Selenium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Selenium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Selenium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "semaglutide",
    "title": "Semaglutide",
    "aliases": [
      "Ozempic",
      "Wegovy",
      "Rybelsus"
    ],
    "category": "GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Semaglutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Semaglutide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Label-based titration generally starts at 0.25 mg weekly and increases in staged 4-week intervals up to product-specific targets. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Weekly adherence with exact injection-day drift tracking.",
      "Nausea, reflux, bowel-pattern, and meal-size tolerance logs.",
      "Weight trend slope and appetite-return timing across weekly curve."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Semaglutide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Semaglutide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Semaglutide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Semaglutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Semaglutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Semaglutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Semaglutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Semaglutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Semaglutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "semax",
    "title": "Semax",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Semax guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Semax appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Semax; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Semax appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Semax: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Semax",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Semax: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Semax",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Semax: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "sermorelin",
    "title": "Sermorelin",
    "aliases": [
      "GHRH 1-29",
      "Sermorelin Acetate"
    ],
    "category": "GH Secretagogue",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Sermorelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Sermorelin is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Common legacy protocols cite 200-1000 mcg nightly with cycle planning and response monitoring. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Sermorelin in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sermorelin: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Sermorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sermorelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sermorelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sermorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sermorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Sermorelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sermorelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "shb",
    "title": "SHB",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SHB guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SHB appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for SHB; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SHB appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SHB: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SHB",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SHB: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SHB",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SHB: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "shr",
    "title": "SHR",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SHR guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SHR appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for SHR; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SHR appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SHR: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SHR",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SHR: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SHR",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SHR: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "sildenafil-viagra",
    "title": "Sildenafil(Viagra)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Sildenafil(Viagra) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Sildenafil(Viagra) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Sildenafil(Viagra); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Sildenafil(Viagra) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sildenafil(Viagra): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sildenafil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sildenafil(Viagra): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sildenafil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sildenafil(Viagra): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "slu-pp-332",
    "title": "SLU-PP-332",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SLU-PP-332 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SLU-PP-332 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for SLU-PP-332; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SLU-PP-332 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SLU-PP-332: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SLU-PP-332",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SLU-PP-332: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SLU-PP-332",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SLU-PP-332: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "slupp-332-250mcg-plus-bam15-50mcg",
    "title": "slupp-332 250mcg+BAM15 50mcg",
    "aliases": [],
    "category": "Compound Blend",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "slupp-332 250mcg+BAM15 50mcg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "slupp-332 250mcg+BAM15 50mcg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for slupp-332 250mcg+BAM15 50mcg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is slupp-332 250mcg+BAM15 50mcg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "slupp-332 250mcg+BAM15 50mcg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=slupp-332%20250mcg%2BBAM15%2050mcg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "slupp-332 250mcg+BAM15 50mcg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=slupp-332%20250mcg%2BBAM15%2050mcg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "slupp-332 250mcg+BAM15 50mcg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "snap-8",
    "title": "SNAP-8",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SNAP-8 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SNAP-8 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for SNAP-8; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SNAP-8 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SNAP-8: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SNAP-8",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SNAP-8: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SNAP-8",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SNAP-8: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "sodium",
    "title": "Sodium",
    "aliases": [
      "Na"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Sodium guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Sodium guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize sodium dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Sodium in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sodium: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/list-all/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sodium: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Sodium",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sodium: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sodium+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "sr9009",
    "title": "SR9009",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SR9009 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SR9009 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for SR9009; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SR9009 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SR9009: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SR9009",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SR9009: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SR9009",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SR9009: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "ss-31",
    "title": "SS-31",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "SS-31 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "SS-31 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for SS-31; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is SS-31 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "SS-31: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=SS-31",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "SS-31: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=SS-31",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "SS-31: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "stanozolol-oil-base-winstrol",
    "title": "STANOZOLOL(Oil base)winstrol",
    "aliases": [
      "STANOZOLOL(Water)winstrol"
    ],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "STANOZOLOL(Oil base)winstrol guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "STANOZOLOL(Oil base)winstrol appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for STANOZOLOL(Oil base)winstrol; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is STANOZOLOL(Oil base)winstrol appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "STANOZOLOL(Oil base)winstrol: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=STANOZOLOLwinstrol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "STANOZOLOL(Oil base)winstrol: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=STANOZOLOLwinstrol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "STANOZOLOL(Oil base)winstrol: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "superdrol",
    "title": "Superdrol",
    "aliases": [
      "Superdrol(Methyldrostanolone)"
    ],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Superdrol guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Superdrol appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Superdrol; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Superdrol appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Superdrol: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Superdrol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Superdrol: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Superdrol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Superdrol: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "supertest-450mg",
    "title": "Supertest 450mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Supertest 450mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Supertest 450mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Supertest 450mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Supertest 450mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Supertest 450mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Supertest%20450mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Supertest 450mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Supertest%20450mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Supertest 450mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "survodutide",
    "title": "Survodutide",
    "aliases": [
      "BI 456906"
    ],
    "category": "Experimental",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Survodutide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Survodutide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Investigational schedules are weekly and follow trial-defined titration to reduce GI adverse effects. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Survodutide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Survodutide: Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=Survodutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Survodutide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Survodutide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Survodutide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Survodutide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Survodutide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Survodutide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "sustanon-250mg",
    "title": "Sustanon 250mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Sustanon 250mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Sustanon 250mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Sustanon 250mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Sustanon 250mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sustanon 250mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sustanon%20250mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sustanon 250mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sustanon%20250mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sustanon 250mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "sustanon-400mg",
    "title": "Sustanon 400mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Sustanon 400mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Sustanon 400mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Sustanon 400mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Sustanon 400mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Sustanon 400mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Sustanon%20400mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Sustanon 400mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Sustanon%20400mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Sustanon 400mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "t3",
    "title": "T3",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "T3 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "T3 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for T3; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is T3 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "T3: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=T3",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "T3: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=T3",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "T3: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "t4",
    "title": "T4",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "T4 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "T4 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for T4; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is T4 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "T4: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=T4",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "T4: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=T4",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "T4: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tadalafil-cialis",
    "title": "Tadalafil(Cialis)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tadalafil(Cialis) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tadalafil(Cialis) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Tadalafil(Cialis); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Tadalafil(Cialis) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tadalafil(Cialis): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tadalafil",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tadalafil(Cialis): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tadalafil",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tadalafil(Cialis): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tamoxifen-nolvadex",
    "title": "Tamoxifen(Nolvadex)",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tamoxifen(Nolvadex) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tamoxifen(Nolvadex) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Tamoxifen(Nolvadex); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Tamoxifen(Nolvadex) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tamoxifen(Nolvadex): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tamoxifen",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tamoxifen(Nolvadex): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tamoxifen",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tamoxifen(Nolvadex): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tb-500",
    "title": "TB-500 (Thymosin Beta-4)",
    "aliases": [
      "Thymosin Beta-4",
      "TB-500(TB4)"
    ],
    "category": "Healing Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TB-500 (Thymosin Beta-4) guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. TB-500 (Thymosin Beta-4) is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Common research-use narratives describe loading phases around 2-10 mg weekly followed by lower-maintenance intervals. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Investigational status means efficacy/safety uncertainty can be significant and rapidly evolving.",
      "Stop self-directed escalation when unexpected adverse effects occur and contact a clinician promptly.",
      "Avoid stacking multiple experimental compounds without explicit medical supervision."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for TB-500 (Thymosin Beta-4) in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?",
      "What is the rationale for choosing this option over approved alternatives in my care plan?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TB-500 (Thymosin Beta-4): Investigational program registry",
        "url": "https://clinicaltrials.gov/search?term=TB-500",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TB-500 (Thymosin Beta-4): DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=TB-500",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TB-500 (Thymosin Beta-4): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TB-500",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "TB-500 (Thymosin Beta-4): PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TB-500+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "tb-500-frag",
    "title": "TB-500 FRAG",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TB-500 FRAG guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TB-500 FRAG appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for TB-500 FRAG; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TB-500 FRAG appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TB-500 FRAG: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TB-500%20FRAG",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TB-500 FRAG: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TB-500%20FRAG",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TB-500 FRAG: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "telmisartan",
    "title": "Telmisartan",
    "aliases": [],
    "category": "Oral Compound",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Telmisartan guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Telmisartan appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Telmisartan; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Telmisartan appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Telmisartan: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Telmisartan",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Telmisartan: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Telmisartan",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Telmisartan: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tesamorelin",
    "title": "Tesamorelin",
    "aliases": [
      "Egrifta"
    ],
    "category": "GH Secretagogue",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tesamorelin guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Tesamorelin is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Approved HIV-lipodystrophy labeling commonly uses 2 mg subcutaneous daily administration. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose timing consistency and protocol adherence over full cycles.",
      "Target outcome notes with date-stamped objective/subjective markers.",
      "Adverse-effect timeline entries with severity and resolution notes."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Tesamorelin in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tesamorelin: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Tesamorelin&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tesamorelin: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tesamorelin",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tesamorelin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tesamorelin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Tesamorelin: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tesamorelin+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "tesamorelin-11mg-plus-ipamorelin-6mg-blend",
    "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend",
    "aliases": [],
    "category": "Research Peptide",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tesamorelin 11mg + Ipamorelin 6mg Blend guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tesamorelin 11mg + Ipamorelin 6mg Blend appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Tesamorelin 11mg + Ipamorelin 6mg Blend; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Use label-approved safety guidance and clinician oversight for any dose or schedule adjustments.",
      "Escalate severe adverse effects or unexpected reactions immediately to a licensed clinician.",
      "Verify contraindications and interaction risks before protocol changes."
    ],
    "providerQuestions": [
      "Is Tesamorelin 11mg + Ipamorelin 6mg Blend appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tesamorelin%2011mg%20%2B%20Ipamorelin%206mg%20Blend",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tesamorelin%2011mg%20%2B%20Ipamorelin%206mg%20Blend",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tesamorelin 11mg + Ipamorelin 6mg Blend: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tesofensine",
    "title": "Tesofensine",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tesofensine guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tesofensine appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Tesofensine; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tesofensine appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tesofensine: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tesofensine",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tesofensine: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tesofensine",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tesofensine: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "test-base-no-ester",
    "title": "TEST BASE (NO Ester)",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST BASE (NO Ester) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST BASE (NO Ester) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for TEST BASE (NO Ester); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST BASE (NO Ester) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST BASE (NO Ester): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20BASE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST BASE (NO Ester): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20BASE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST BASE (NO Ester): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "test-cypionate",
    "title": "TEST CYPIONATE",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST CYPIONATE guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST CYPIONATE appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for TEST CYPIONATE; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST CYPIONATE appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST CYPIONATE: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20CYPIONATE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST CYPIONATE: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20CYPIONATE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST CYPIONATE: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "test-enanthate",
    "title": "TEST ENANTHATE",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST ENANTHATE guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST ENANTHATE appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for TEST ENANTHATE; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST ENANTHATE appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST ENANTHATE: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20ENANTHATE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST ENANTHATE: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20ENANTHATE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST ENANTHATE: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "test-p",
    "title": "TEST P",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST P guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST P appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for TEST P; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST P appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST P: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20P",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST P: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20P",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST P: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "test-suspension-100mg",
    "title": "TEST SUSPENSION 100mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST SUSPENSION 100mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST SUSPENSION 100mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for TEST SUSPENSION 100mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST SUSPENSION 100mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST SUSPENSION 100mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20SUSPENSION%20100mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST SUSPENSION 100mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20SUSPENSION%20100mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST SUSPENSION 100mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "test-undecanoate-300",
    "title": "TEST Undecanoate 300",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TEST Undecanoate 300 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TEST Undecanoate 300 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for TEST Undecanoate 300; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TEST Undecanoate 300 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TEST Undecanoate 300: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TEST%20Undecanoate%20300",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TEST Undecanoate 300: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TEST%20Undecanoate%20300",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TEST Undecanoate 300: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "testo-600mg",
    "title": "Testo 600mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Testo 600mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Testo 600mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Testo 600mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Testo 600mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Testo 600mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Testo%20600mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Testo 600mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Testo%20600mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Testo 600mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "thymosin-alpha-1",
    "title": "Thymosin Alpha-1",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Thymosin Alpha-1 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Thymosin Alpha-1 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Thymosin Alpha-1; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Thymosin Alpha-1 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Thymosin Alpha-1: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Thymosin%20Alpha-1",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Thymosin Alpha-1: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Thymosin%20Alpha-1",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Thymosin Alpha-1: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "thymulin",
    "title": "Thymulin",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Thymulin guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Thymulin appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Thymulin; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Thymulin appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Thymulin: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Thymulin",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Thymulin: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Thymulin",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Thymulin: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tirzepatide",
    "title": "Tirzepatide",
    "aliases": [
      "Mounjaro",
      "Zepbound"
    ],
    "category": "GIP/GLP-1",
    "status": "approved",
    "statusLabel": "Approved",
    "metaDescription": "Tirzepatide guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes labeled-use context and practical tracking priorities for clinician discussions. Tirzepatide is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Label pathways start at 2.5 mg weekly and escalate stepwise to 5, 7.5, 10, 12.5, and 15 mg as tolerated. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Dose-day consistency and any delayed/early administration changes.",
      "Energy, appetite suppression, and GI tolerance by day since dose.",
      "Weight and waist trend snapshots on consistent weekly cadence."
    ],
    "safetyFlags": [
      "Escalate severe GI symptoms, dehydration, persistent vomiting, or signs of allergic reaction immediately.",
      "Do not change dose frequency or amount without licensed clinician direction.",
      "Confirm contraindications, interactions, and renal/hepatic considerations before protocol changes."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Tirzepatide in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tirzepatide: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Tirzepatide&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tirzepatide: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tirzepatide",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tirzepatide: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tirzepatide",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Tirzepatide: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tirzepatide+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "tren-a",
    "title": "Tren A",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren A guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren A appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Tren A; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren A appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren A: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20A",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren A: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20A",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren A: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tren-base",
    "title": "Tren BASE",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren BASE guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren BASE appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Tren BASE; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren BASE appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren BASE: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20BASE",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren BASE: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20BASE",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren BASE: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tren-e",
    "title": "Tren E",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren E guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren E appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Tren E; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren E appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren E: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20E",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren E: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20E",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren E: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tren-hex",
    "title": "Tren Hex",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Tren Hex guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Tren Hex appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Tren Hex; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Tren Hex appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Tren Hex: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Tren%20Hex",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Tren Hex: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Tren%20Hex",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Tren Hex: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "trenmix-200mg",
    "title": "TRENMIX 200mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TRENMIX 200mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TRENMIX 200mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for TRENMIX 200mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TRENMIX 200mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TRENMIX 200mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TRENMIX%20200mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TRENMIX 200mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TRENMIX%20200mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TRENMIX 200mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "tritren-225mg",
    "title": "TriTren 225mg",
    "aliases": [],
    "category": "Injectable Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "TriTren 225mg guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "TriTren 225mg appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for TriTren 225mg; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track injection date/time, site rotation, concentration, and volume used each administration.",
      "Log acute post-injection effects and delayed responses in consistent windows.",
      "Document cycle start/stop dates and rationale before any protocol change."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is TriTren 225mg appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "TriTren 225mg: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=TriTren%20225mg",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "TriTren 225mg: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=TriTren%20225mg",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "TriTren 225mg: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "turinabol",
    "title": "Turinabol",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Turinabol guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Turinabol appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Turinabol; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Turinabol appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Turinabol: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Turinabol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Turinabol: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Turinabol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Turinabol: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "vilon",
    "title": "Vilon",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Vilon guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Vilon appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Vilon; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Vilon appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Vilon: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Vilon",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Vilon: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Vilon",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Vilon: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "vip",
    "title": "VIP",
    "aliases": [],
    "category": "Research Peptide",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "VIP guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "VIP appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for VIP; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Document exact dose timing and whether compound is used solo or in a blend stack.",
      "Track target outcomes with date-stamped notes and objective trend markers where possible.",
      "Log adverse effects with onset, peak, and resolution windows to support safer follow-up."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is VIP appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "VIP: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=VIP",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "VIP: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=VIP",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "VIP: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "vitamin-d3",
    "title": "Vitamin D3",
    "aliases": [
      "Cholecalciferol"
    ],
    "category": "Vitamin",
    "status": "nutrient",
    "statusLabel": "Nutrient Support",
    "metaDescription": "Vitamin D3 guide for dosing context, tracking priorities, safety red flags, and provider discussion prompts in ShotClock.",
    "heroSummary": "This guide summarizes investigational or non-standard context and prioritizes conservative risk framing for clinician review. Vitamin D3 is presented as educational content only and not a prescription directive.",
    "dosingSection": {
      "overview": "Common replacement plans range from 1000-5000 IU daily, with higher short-course repletion plans based on labs. [C1]",
      "protocolPatterns": [
        "Dose escalation or schedule changes should be tied to objective tolerance logs and clinician checkpoints. [C2]",
        "When protocols involve cycles or stacks, document start/stop dates and decision criteria before changes. [C3]"
      ],
      "monitoringWindows": [
        "Log weekly trend checkpoints at the same day/time to reduce interpretation noise. [C2]",
        "Record adverse-effect onset, peak, and resolution timing to support safer follow-up decisions. [C4]"
      ]
    },
    "trackingSignals": [
      "Administration consistency and lab follow-up dates.",
      "Energy, neurologic, or musculoskeletal symptom trends over weeks.",
      "Route tolerance and adherence barriers."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Vitamin D3 in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Vitamin D3: FDA/openFDA labeling and safety records",
        "url": "https://api.fda.gov/drug/label.json?search=openfda.generic_name:Vitamin%20D3&limit=1",
        "sourceType": "FDA API",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Vitamin D3: DailyMed labeling index",
        "url": "https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Vitamin%20D3",
        "sourceType": "DailyMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Vitamin D3: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Vitamin%20D3",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C4",
        "title": "Vitamin D3: PubMed evidence reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Vitamin%20D3+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  },
  {
    "slug": "winstrol-stanozolol",
    "title": "Winstrol(Stanozolol )",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "Winstrol(Stanozolol ) guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "Winstrol(Stanozolol ) appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for Winstrol(Stanozolol ); clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is Winstrol(Stanozolol ) appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Winstrol(Stanozolol ): PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Winstrol",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Winstrol(Stanozolol ): Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=Winstrol",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Winstrol(Stanozolol ): FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "yk11",
    "title": "YK11",
    "aliases": [],
    "category": "Oral Compound",
    "status": "experimental",
    "statusLabel": "Experimental",
    "metaDescription": "YK11 guide covering dosing context from available literature, tracking priorities, safety signals, and provider discussion prompts.",
    "heroSummary": "YK11 appears in the supplier catalog list and is documented here for educational orientation, tracking structure, and risk-aware provider conversations.",
    "dosingSection": {
      "overview": "Commercial listings show multiple strengths and formats for YK11; clinical dosing decisions should be made only with licensed medical guidance. [C1]",
      "protocolPatterns": [
        "If used, define a clear protocol window, objectives, and stop criteria before starting. [C2]",
        "Avoid unsupervised stacking and avoid copying vendor-table schedules as medical instructions. [C3]"
      ],
      "monitoringWindows": [
        "Track adherence, symptoms, and context notes on a consistent schedule for better interpretation quality. [C1]",
        "Escalate unexpected adverse effects early and document timing relative to administration. [C2]"
      ]
    },
    "trackingSignals": [
      "Track adherence by day and time, especially around meal timing and missed doses.",
      "Log response trends (energy, appetite, mood, training tolerance, or symptom shifts) consistently.",
      "Record side effects and any interaction concerns with existing prescriptions or supplements."
    ],
    "safetyFlags": [
      "Investigational compounds may have limited long-term safety and efficacy evidence.",
      "Avoid self-directed escalation or high-risk stacking without explicit medical supervision.",
      "Stop use and seek clinical guidance if unexpected adverse events occur."
    ],
    "providerQuestions": [
      "Is YK11 appropriate for my goals and risk profile compared with established alternatives?",
      "Which baseline and follow-up labs or vitals should be tracked, and at what cadence?",
      "Which side effects should trigger urgent contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "YK11: PubMed clinical evidence and reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=YK11",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "YK11: Clinical trials registry",
        "url": "https://clinicaltrials.gov/search?term=YK11",
        "sourceType": "ClinicalTrials.gov",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "YK11: FDA drug information lookup",
        "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
        "sourceType": "FDA",
        "publisher": "U.S. Food and Drug Administration",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.1.0"
  },
  {
    "slug": "zinc",
    "title": "Zinc",
    "aliases": [
      "Zn"
    ],
    "category": "Mineral",
    "status": "nutrient",
    "statusLabel": "Mineral Support",
    "metaDescription": "Zinc guide with evidence-linked intake context, safety limits, tracking cues, and provider questions.",
    "heroSummary": "Zinc guidance is educational and should be individualized with labs, renal/cardiac context, and clinician input.",
    "dosingSection": {
      "overview": "Use lab status, dietary intake, kidney function, and indication to individualize zinc dosing strategy. [C1]",
      "protocolPatterns": [
        "Start with conservative supplementation ranges when clinically appropriate, then adjust using objective labs. [C1]",
        "Account for interactions with current medications, thyroid/renal status, and gastrointestinal tolerance. [C2]"
      ],
      "monitoringWindows": [
        "Define recheck intervals before starting supplementation so adjustments are data-guided. [C1]",
        "Track symptom trend plus objective biomarkers to avoid long, unverified high-dose exposure. [C3]"
      ]
    },
    "trackingSignals": [
      "Intake consistency and co-administered supplement timing.",
      "Symptom trends tied to deficiency or excess risk windows.",
      "Relevant lab checkpoints and clinician follow-up dates."
    ],
    "safetyFlags": [
      "High-dose nutrient plans can still cause toxicity or interaction risk and require lab-guided follow-up.",
      "Coordinate with current medications (for example thyroid, anticoagulant, or renal regimens).",
      "Escalate signs of overload, deficiency progression, or unexpected neurologic/cardiac symptoms."
    ],
    "providerQuestions": [
      "What outcome targets should define success or failure for Zinc in my case?",
      "Which baseline and follow-up labs should be scheduled, and at what intervals?",
      "What side-effect thresholds should trigger same-day clinician contact versus routine follow-up?"
    ],
    "citations": [
      {
        "id": "C1",
        "title": "Zinc: NIH ODS health professional fact sheet",
        "url": "https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/",
        "sourceType": "NIH ODS",
        "publisher": "National Institutes of Health",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C2",
        "title": "Zinc: MedlinePlus evidence and safety context",
        "url": "https://medlineplus.gov/?query=Zinc",
        "sourceType": "MedlinePlus",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      },
      {
        "id": "C3",
        "title": "Zinc: PubMed clinical reviews",
        "url": "https://pubmed.ncbi.nlm.nih.gov/?term=Zinc+supplementation+review",
        "sourceType": "PubMed",
        "publisher": "U.S. National Library of Medicine",
        "publishedDate": "2025-01-01",
        "accessedDate": "2026-02-22"
      }
    ],
    "lastReviewed": "2026-02-22",
    "version": "1.0.0"
  }
]
